Newsgroup: it.economia.borsa
Titolo: ecco le cell

si riparte
un saluto a Kiss

      Survival Benefit Linked to Estrogen in Women Treated With XYOTAX(TM)
    Third Clinical Trial in First-Line Lung Cancer to Demonstrate Superior
                       Survival in Pre-Menopausal WomenNEW YORK, Feb. 15
/PRNewswire-FirstCall/ -- In a presentation at the BIO CEO & Investor
conference today, James A. Bianco, M.D., President and CEO of Cell
Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) presented updated results
of a phase II study of XYOTAX in combination with carboplatin among 35 women
and 39 men with advanced non-small cell lung cancer (NSCLC). Unlike the
STELLAR 3 and 4 trials, where only patients with poor performance status
(PS2) were enrolled, there was no restriction on performance status in the
phase II trial, known as PGT202. The study was analyzed for overall survival
by gender and by estrogen levels to confirm the observation of enhanced
efficacy in the presence of estrogen seen in the STELLAR first-line trials.
Estimated one-year survival of women receiving XYOTAX is 36 percent compared
to only 16 percent of their male counterparts. Consistent with the results
seen in the STELLAR 3 trial (XYOTAX/carboplatin), the 12 women with normal
estrogen levels (>/=30 pg/ml) survived longer than the 22 women with
post-menopausal, low estrogen levels. The estimated median survival for
women with low estrogen levels was 128 days (4.2 months) while the median
survival among women with normal estrogen levels was 218 days (7.2 months).
At the time of last contact, nine of 12 women (75 percent) with normal
estrogen levels were alive compared to nine of 22 women (41 percent) with
low estrogen levels.
      "This phase II study supports what we observed and reported in our
prior first-line study of XYOTAX and carboplatin (STELLAR 3) and
substantially strengthens the likelihood that the beneficial effect of
estrogen on XYOTAX efficacy is valid," stated Bianco. "This gives us a high
degree of confidence that we are on the right path by investing in the
PIONEER gender-specific study and broadens the potential applicability to
all first-line patients, not just PS2 patients."
      In a composite analysis of two prior randomized trials (STELLAR 3 and
4), in 198 women with advanced NSCLC who were PS2, patients randomized to
receive XYOTAX had a statistically significant improvement in overall
survival compared to women treated with comparator agents (hazard ratio
0.70, log rank p=0.03) with one-year survival estimates of 40% vs. 25%
(p=0.01). Results among men were similar to the comparator agents. The most
common side effects were neuropathy and myelosuppression. Survival
significantly correlated with pre-menopausal age and pre-menopausal estrogen
levels, where available, consistent with preclinical findings showing that
estrogen enhances the biodistribution and release of paclitaxel from the
polyglutamate polymer in tumor-bearing tissues, such as the lungs, allowing
potentially greater tumor exposure to chemotherapy than can be achieved with
standard chemotherapy agents

 un saluto a Kiss
auguri x il breve viaggio... :-D

 Nel suo scritto precedente, mascheroni ® ha sostenuto :
auguri x il breve viaggio... :-D
http://img113.imageshack.us/my.php?image=021520061946130zz.png


grazie, ci vediamo il pių tardi possibile
tu come vedo sempre in sala di attesa.........

Cell Therapeutics,donne trattate con Xyotax vivono più di uomini
MILANO, 15 febbraio (Reuters) - Cell Therapeutics
informa che "nell'ambito dello studio di fase II del farmaco Xyotax in
combinazione con carboplatino su 35 donne e 39 uomini affetti da tumore
polmonare non microcitoma avanzato, la sopravvivenza a un anno nelle donne
che hanno ricevuto Xyotax è risultata pari al 36%, rispetto al solo 16%
della componente maschile". Lo dice una nota. "Questo studio rafforza
l'ipotesi che gli estrogeni abbiano un effetto favorevole sull'efficiacia di
Xyotax. Inoltre viene ampliata la potenziale applicabilità di Xyotax a tutti
i pazienti in prima linea, non solo a quelli PS2", nota James Bianco, AD di
Cell Therapeutics. ((Redazione Milano, Reuters Messaging

 in combinazione con carboplatino su 35 donne e 39 uomini affetti da 
CUT
vista la moria di pollastri, con questa news ne hanno resuscitati un 
bel po'...

 bel po'...
mandagli un messaggio e digli di dare solo notizie negative
altrimenti gli mandi un'ispezione sanitaria
ps:fai attenzione,manca ancora 1 ora e mezza alla chiusura, non ti distrarre